Anthera Pharmaceuticals, Inc. Plans $70 Million IPO
9/16/2009 8:59:59 AM
More...
|
Anthera Pharmaceuticals, Inc.'s Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
5/6/2009 7:38:00 AM
More...
|
Following Encouraging Results Anthera Pharmaceuticals, Inc. to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
3/24/2009 9:40:01 AM
More...
|
Anthera Pharmaceuticals, Inc. Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
1/12/2009 9:01:06 AM
More...
|
Anthera Pharmaceuticals, Inc.'s Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
11/11/2008 9:13:58 AM
More...
|
Anthera Pharmaceuticals, Inc. Completes Special Protocol Assessment With FDA and Receives European Medicines Evaluation Agency Scientific Advice on Development Path Toward Varespladib Approval
9/24/2008 8:36:49 AM
More...
|
Anthera Pharmaceuticals, Inc. Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8/25/2008 8:15:12 AM
More...
|
Anthera Pharmaceuticals, Inc. Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8/13/2008 6:58:31 AM
More...
|
Anthera Pharmaceuticals, Inc. Presents Data on Varespladib
4/18/2008 8:21:20 AM
More...
|
Anthera Pharmaceuticals, Inc. Says DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4/16/2008 8:23:16 AM
More...
|
|